Noble Life Sciences (Gaithersburg, MD), in collaboration with ImQuest BioSciences (Frederick, MD), has successfully developed a neutropenic mouse thigh model of infection and demonstrated its use in a study evaluating vancomycin for the treatment of Staphylococcus aureus infection.
The model will serve as a new Noble service for the evaluation of the efficacy of novel anti-microbial compounds in the treatment of microbial infections.
Complicated skin and soft tissue infections are frequently encountered in clinical practice and are a significant cause of morbidity and mortality in hospitalized patients.
The neutropenic mouse thigh model of infection has been used extensively to test and benchmark antimicrobial drugs leading to a significant impact on our current knowledge of antimicrobial pharmacology.
This model allows the quantitative comparison of different agents and different dosing regimes and the determination of the time-course of antimicrobial activity under conditions optimal for efficacy, i.e., neutropenia.
Alain Cappeluti, President of Noble Life Sciences, noted, “The optimization of this model is the result of a collaborative effort combining the animal model and drug development expertise of Noble Life Sciences with the microbiology expertise of ImQuest BioSciences.”
“We are pleased with our collaboration with Noble Life Sciences in the optimization of this model. The model should be of particular interest to companies developing antimicrobial drugs that will expand the choices available to physicians facing increasing antimicrobial resistance,” commented Bob Buckheit, CEO and President of ImQuest BioSciences.